Simon J Little

The 2.5% convertible senior notes are due 2029

The 2.5% convertible notes are due 2030

We advised the acquirer of Truphone’s assets in a pre-packaged English administration

We advised an ad hoc group of investors on Avianca’s DIP-to-exit financing

We are advising Tencent on the recommended cash offer by its indirect subsidiary

We advised Gyroscope Therapeutics on its private placement of preferred stock

Davis Polk advised Royalty Pharma plc and the selling shareholders on Royalty Pharma’s $728 million secondary offering of 17,343,037 of its Class A ordinary shares by certain selling…

Davis Polk advised Royalty Pharma plc in connection with its Rule 144A/Regulation S offering of $1 billion aggregate principal amount of its 0.75% senior notes due 2023, $1 billion…

Davis Polk advised Freeline Therapeutics Holdings plc on its $158.8 million initial public offering of 8,823,529 American depositary shares representing 8,823,529 ordinary shares, which…

Davis Polk advised Royalty Pharma plc and the selling shareholders on Royalty Pharma’s $2.5 billion initial public offering of 89,333,920 of its Class A ordinary shares, which included an…